Table Of Contents

1. Introduction 14
1.1. Objectives Of The Study 14
1.2. Market Definition 14
1.3. Overview Of North America Hla Typing Transplant Diagnostics Services Market 14
1.4. Currency And Pricing 15
1.5. Limitation 15
1.6. Markets Covered 16
2. Market Segmentation 18
2.1. Markets Covered 18
2.2. Geographic Scope 19
2.3. Years Considered For The Study 20
2.4. Currency And Pricing 20
2.5. Research Methodology 21
2.6. Primary Interviews With Key Opinion Leaders 24
2.7. Secondary Sources 25
2.8. Assumptions 25
3. Market Overview 26
3.1. Drivers 28
3.1.1. Technological Advancements In Hla Typing 28
3.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures 29
3.1.3. Increased Research Grants, Funds, And Public-Private Investments 29
3.2. Restraints 30
3.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures 30
3.2.2. Expensive Ngs And Pcr-Based Devices 30
3.3. Opportunities 31
3.3.1. Rising Healthcare Infrastructure In Emerging Nations 31
3.4. Challenges 32
3.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually 32
3.4.2. Lack Of Trained Staff 33
4. Executive Summary 34
5. Premium Insights 36
6. North America Hla Typing Transplant Diagnostics Services Market, By Technology 39
6.1. Overview 40
6.2. Next-Generation Sequencing (Ngs) 42
6.3. Polymerase Chain Reaction (Pcr) 43
6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide) 44
6.3.2. Pcr Ssp (Sequence-Specific Primer) 44
6.3.3. Pcr-Sbt (Sequencing Based Typing) 45
7. North America Hla Typing Transplant Diagnostics Services Market, By End-User 46
7.1. Overview 47
7.2. Specialty Clinics 49
7.3. Hospitals 50
7.4. Transplant Centers 51
7.5. Academic Institutes 52
8. North America Hla Typing Transplant Diagnostics Services Market, By Geography 53
8.1. North America 53
8.1.1. U.S. 61
8.1.2. Canada 63
8.1.3. Mexico 65
9. North America Hla Typing Transplant Diagnostics Services Market, Company Landscape 67
9.1. Company Share Analysis; North America 67
10. Company Profiles 68
10.1. Proimmune Ltd. 68
10.1.1. Company Overview 68
10.1.2. Proimmune Ltd.; Company Snapshot 68
10.1.3. Product Portfolio 69
10.1.4. Recent Developments 69
10.2. Creative Biolabs 70
10.2.1. Company Overview 70
10.2.2. Creative Biolabs; Company Snapshot 70
10.2.3. Product Portfolio 70
10.2.4. Recent Developments 70
10.3. Histogenetics Llc 71
10.3.1. Company Overview 71
10.3.2. Histogenetics Llc; Company Snapshot 71
10.3.3. Product Portfolio 71
10.3.4. Recent Developments 71
10.4. The Ucla Immunogenetics Center 72
10.4.1. Company Overview 72
10.4.2. The Ucla Immunogenetics Center; Company Snapshot 72
10.4.3. Product Portfolio 72
10.4.4. Recent Developments 72
10.5. Admera Health 73
10.5.1. Company Overview 73
10.5.2. Admera Health; Company Snapshot 73
10.5.3. Product Portfolio 74
10.5.4. Recent Developments 74
10.6. Quick Biology 75
10.6.1. Company Overview 75
10.6.2. Quick Biology; Company Snapshot 75
10.6.3. Product Portfolio 75
10.6.4. Recent Developments 75
10.7. New York Blood Center 76
10.7.1. Company Overview 76
10.7.2. New York Blood Center; Company Snapshot 76
10.7.3. Product Portfolio 76
10.7.4. Recent Developments 76
10.8. The Sequencing Center 77
10.8.1. Company Overview 77
10.8.2. The Sequencing Center; Company Snapshot 77
10.8.3. Product Portfolio 78
10.8.4. Recent Developments 78
10.9. Bloodcenter Of Wisconsin 79
10.9.1. Company Overview 79
10.9.2. Bloodcenter Of Wisconsin; Company Snapshot 79
10.9.3. Product Portfolio 79
10.9.4. Recent Developments 79
10.10. Laboratory Corporation Of America Holdings 80
10.10.1. Company Overview 80
10.10.2. Laboratory Corporation Of America Holdings; Revenue Analysis 80
10.10.3. Product Portfolio 81
10.10.4. Recent Developments 81
10.11. Thermo Fisher Scientific Inc. 82
10.11.1. Company Overview 82
10.11.2. Thermo Fisher Scientific Inc. ;Revenue Analysis 82
10.11.3. Product Portfolio 83
10.11.4. Recent Developments 83
11. Related Reports 84